THERAPY DOSSIER · th-acf70ea69c03

Copper-zinc superoxide dismutase 1 double-coat cross-linked polyion complex nanozyme with PEG-polylysine and PEG-polyglutamic acid

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29196042 ↗2017Reported benefit

Multilayer polyion complex nanoformulations of superoxide dismutase 1 for acute spinal cord injury.

RatSpinal cord injuryContusionSprague-Dawley and Wistar (MeSH indexed)Male and female (MeSH indexed)Intravenous5 kU of SOD1 per kg

Model: Moderate contusion spinal cord injury in rats; model details not stated in abstract

A single intravenous dose of double-coat SOD1 nanozyme prolonged circulation of active SOD1 (half-life 60 versus 6 min) and improved locomotor recovery while reducing swelling, cord compression and post-traumatic cyst formation after moderate spinal cord injury

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…